The FDA nod marks a step forward in precision oncology, linking molecular diagnostics more tightly to therapy selection for advanced prostate cancer
New Shoolagiri plant strengthens Maiva’s global CDMO capabilities with advanced isolator technology, flexible production lines, and expanded capacity for complex injectable therapies
Dr Reddy’s has partnered with MSN Laboratories Private Limited on the product, with Dr Reddy’s holding exclusive US marketing rights while MSN leads development and manufacturing
New-generation cardiac ablation technology expands treatment options for atrial fibrillation patients, offering a non-thermal approach to improve safety and procedural efficiency
Exclusive licensing agreement combines Lonza’s dual-payload ADC technology with Antharis’ antibody engineering expertise
The decision was driven by results from the Phase III CAPItello-281 trial,
MeRT becomes one of the few FDA-cleared neuromodulation therapies for PTSD, using EEG biomarkers and AI to personalize treatment for patients with treatment-resistant symptoms
Approval is based on results from the phase 3 OASIS 4 clinical trial
Dr. Quirk said the program’s mechanism offers a targeted approach to disrupted brain signaling in compulsivity-related disorders
Knowledge paper highlights biosimilars, biologics, AI-driven drug discovery and regulatory excellence as key growth drivers for the next phase of India's pharma expansion
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
